OptimizeRx Q2 2024 Adj. EPS $0.02 Beats $(0.06) Estimate, Sales $18.812M Miss $20.195M Estimate
Portfolio Pulse from Benzinga Newsdesk
OptimizeRx (NASDAQ:OPRX) reported Q2 2024 adjusted EPS of $0.02, beating the $(0.06) estimate, but sales of $18.812M missed the $20.195M estimate. EPS improved by 300% year-over-year, while sales increased by 36.14%.
August 08, 2024 | 8:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
OptimizeRx reported Q2 2024 adjusted EPS of $0.02, beating the $(0.06) estimate, but sales of $18.812M missed the $20.195M estimate. EPS improved by 300% year-over-year, while sales increased by 36.14%.
The significant beat on EPS, which exceeded expectations by 133.33%, is likely to have a positive impact on the stock price. However, the miss on sales by 6.85% may temper some of the enthusiasm. Overall, the strong improvement in EPS and sales growth year-over-year should be viewed positively by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100